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Abstract
Background: There is substantial scope for improvement in the current arsenal of smoking cessation methods and
techniques: even when front-line cessation treatments are utilized, smokers are still more likely to fail than to succeed.
Studies testing the incremental benefit of using nicotine patch for 1–4 weeks prior to quitting have shown pre-quit
nicotine patch use produces a robust incremental improvement over standard post-quit patch treatment. The
primary objective of the current study is to test the mechanism of action of two pre-quit smoking cessation
medications—varenicline and nicotine patch—in order to learn how best to optimize these pre-quit treatments.
Methods/Design: The study is a three group, randomized, open-label controlled clinical trial. Participants (n = 216
interested quitters) will be randomized to receive standard patch treatment (10 weeks of patch starting from a
designated quit day), pre-quit patch treatment (two weeks of patch treatment prior to a quit day, followed by 10
weeks post-quit treatment) or varenicline (starting two weeks prior to quit day followed by 10 weeks post-quit).
Participants will use study-specific modified smart-phones to monitor their smoking, withdrawal symptoms, craving,
mood and social situations in near real-time over four weeks; two weeks prior to an assigned quit date and two weeks
after this date. Smoking and abstinence will be assessed at regular study visits and biochemically verified.
Discussion: Understanding how nicotine patches and varenicline influence abstinence may allow for better tailoring of
these treatments to individual smokers.
Trial registration: Australian New Zealand Clinical Trials Registry, ACTRN12614000329662 (Registered: 27 March 2014).
Keywords: Nicotine patch, Varenicline, Pre-quit treatment, Smoking reduction
Background
Cigarette smoking remains one of the leading causes
of preventable death and disease worldwide [1, 2]. Per-
haps not surprisingly, the majority of smokers indicate
that they would like to quit [3]; despite this interest in
quitting, however, the proportion of smokers who success-
fully quit each year is very low. Poor cessation rates can
partly be attributed to the low uptake of efficacious smok-
ing cessation methods [4]—a review [5] of unassisted
(“cold turkey”) quit attempts concluded that the vast
majority end in failure; however, even when smokers
adopt effective cessation methods the most likely outcome
is still failure. Even with the currently accepted gold
standard treatment (i.e., pharmacotherapy combined
with behavioural counselling) approximately 70 % [6, 7] of
quit efforts fail. Thus, not only do interested quitters
eschew current smoking cessation methods more often
than not, but also when they are used they afford only
modest improvements in the overall likelihood of quit-
ting. Developing efficacious treatments that are accessible
to a wide range of smokers will reduce tobacco-related
deaths [8].
Numerous studies have been conducted over the last
two decades aimed at developing new smoking cessation
methods and treatments (e.g., [9, 10]), with some notable
successes [11]. An alternate approach, however, is to
optimize the use of existing smoking cessation methods
and agents: improvements in quit rates can come from
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innovations in the way currently available treatments
are used. Nicotine patch—a form of Nicotine Replace-
ment Therapy (NRT)—is the most widely used pharma-
cotherapy to aid smoking cessation [4]. Patch treatment
approximately doubles a smoker’s chance of maintaining
longer-term abstinence (compared to placebo treatment)
[7]. Nicotine patch was originally approved as an aid to
abrupt cessation: smokers were instructed to stop smok-
ing entirely and then start using the medication [7]. More
recently, researchers have started to explore alternative
methods of using patch, with an eye towards improving its
effectiveness (e.g., [12, 13]). One alternative that has been
of particular interest to researchers has been the incre-
mental benefit of using nicotine patch for 1–4 weeks prior
to quitting (so called nicotine “preloading” [14]), followed
by the standard post-quit patch regime. Studies showed
that nicotine patch preloading improves treatment effi-
cacy: pre-quit nicotine patch use appears to produce a
robust incremental improvement over standard patch
treatment [14–16].
Why might using nicotine patch prior to quitting aid
smoking cessation over and above the standard regime
of starting patch on quit day? The most commonly
voiced mechanism is that the non-contingently delivered
nicotine from pre-quit nicotine patch treatment makes
cigarettes less satisfying, thus blunting the reinforcement
gained from smoking; this reduced satisfaction drives
smoking reduction and subsequent cessation [14, 15].
Some support for this mechanism can be found in the
nicotine patch literature. Previous studies have found
that smokers rate cigarettes smoked while wearing a
nicotine patch as less satisfying (e.g., [17–19]; c.f., [20])
and that the satisfaction obtained from smoking lapses
predicts subsequent abstinence [20]. However, rando-
mised studies that have examined pre-quit nicotine patch
treatment’s effect on smoking satisfaction during the pre-
quit period have found mixed results [15].
One reason for the mixed findings could be due to
methodological shortcomings of the studies conducted
to date. Studies of pre-quit nicotine patch use have
typically relied on a participant’s retrospective recall
to gather information on the effects of smoking while
using patch. Such approaches are prone to systematic
errors and bias [21–23]; these biases can mask legit-
imate trends in the data, and potentially lead to spurious
conclusions.
More recently, our group conducted a small (n = 61)
feasibility study designed to test the effect of pre-quit
nicotine patch treatment on satisfaction gained from
smoking. Using a single-group design [19], interested
quitters monitored their smoking, affect and activities
during two weeks of pre-quit nicotine patch treatment.
In order to reduce the need for retrospective recall, data
were collected in real-time using hand-held computers
[22]. Participants were then followed-up after four weeks
of post-quit treatment and abstinence was assessed. As
expected, both smoking rate and satisfaction with smok-
ing declined during the pre-quit nicotine patch period,
and further analysis suggested that the degree of reduc-
tion achieved during the pre-quit period was related to
the likelihood of abstinence at the four-week follow-up,
although this relationship was not significant [19]. While
these results are supportive of the posited mechanism of
action, the absence of a control group meant that the
study could not determine whether it was actually the
pre-quit nicotine patch treatment that was driving the
reductions in satisfaction and smoking rate observed
during the pre-quit phase. The current study was designed
to overcome this limitation by including a control group
of participants who started nicotine patch treatment on
quit day.
Nicotine patch is not the only smoking cessation
pharmacotherapy to be used prior to quit: varenicline is
also typically started 1–2 weeks prior to a quit attempt.
Varenicline is the newest pharmacological smoking ces-
sation agent and has been found to be more effective
than other mono-therapies [6]. Interestingly, studies (e.g.,
[24]) have suggested that, like pre-quit nicotine patch
treatment, the efficacy of varenicline may also, at least in
part, be mediated via reductions in the satisfaction gained
from smoking. Understanding how these two pre-quit
agents influence abstinence may allow for better tailoring
of treatment (e.g., if the proposed mechanism of action is
confirmed, it may be beneficial to tailor the length of the
pre-quit treatment phase until sufficient reduction has
occurred, or to use reduction as an early indicator of treat-
ment effectiveness [25]). Furthermore, understanding the
effects of pre-quit treatment may provide targets for new
medications.
The study will use a three-group, randomised, open-
label study design. Participants will be randomized to
one of two pre-quit treatment conditions, or a control
group. Participants in the active pre-quit conditions will
received two weeks of active medication treatment (nico-
tine patch or varenicline) prior to an assigned quit day,
followed by up to 10 weeks of post-quit treatment; partici-
pants randomized to the control group will receive up to
10 weeks of nicotine patch treatment starting from their
assigned quit day (so no treatment during the pre-quit
phase). Using this design we plan to test four hypotheses:
1) Participants in the pre-quit treatment conditions will
experience a significant reduction in the satisfaction
gained from smoking over the two-week pre-quit period
(compared to participants in the control group); 2) Partici-
pants in the pre-quit treatment conditions will experience
a significant reduction in craving over the two-week
pre-quit period (compared to participants in the con-
trol group); 3) Participants in the pre-quit treatment
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conditions will significantly reduce smoking rate over the
two-week pre-quit period (compared to participants in the
control group); and 4) Smoking reduction during the pre-
quit phase will be positively associated with abstinence at
four-week follow-up. A secondary objective of the study
will be to look for moderators of treatment outcome (e.g.,
nicotine metabolism [26]) and to explore the effect of pre-
quit treatment on lapses that occur post-quit.
Methods
Overview
Interested quitters will be monitored for two weeks be-
fore, and four weeks after, a quit attempt. Participants
will be randomized to a Varenicline Group, a Pre-Quit
Patch Group, or a Standard Patch Group. Participants
randomized to the Standard Patch Group will receive
nicotine patch treatment starting from their assigned
quit day. Participants in the Pre-Quit Patch and Vareni-
cline groups will receive two weeks of active medication
treatment prior to an assigned quit day, followed by up
to 10 weeks of post-quit medication. All participants
will use a customized smart-phone [22] to monitor their
smoking, affect, and activities in real-time for four weeks
(two weeks prior to an assigned quit date and two weeks
after this date). Abstinence will be assessed at regular
study visits.
Design
The study will use a three group, randomized, open-
label controlled clinical trial study design.
Participant recruitment
A community sample of interested quitters will be re-
cruited from the greater Hobart (Tasmania, Australia)
region using advertisements in local newspapers, flyers,
and through targeted advertisements on social media
websites such as Facebook [27].
Inclusion/Exclusion criteria
To be eligible for enrolment, interested individuals will
have to report: a) being ≥18 years old; b) smoking ≥10
cigarettes per day for the past three years; c) having a
high motivation to quit smoking; d) be willing to use
either patches or varenicline as part of a quit attempt;
e) being able to read and write English; and f ) be
willing to consent to and complete the research tasks.
Potential participants will be excluded if they: a) are
currently enrolled in a smoking cessation trial, or have
been within the past three months; or b) are unsuitable
for treatment with either patches or varenicline (per
current Australian prescribing guidelines [28]). Specific-
ally, interested smokers will be excluded if they: Are a
diabetic; have a mental illness or a history of repeated fits
or convulsions (epilepsy); have kidney or liver problems;
have a skin condition or disease such as allergic eczema or
dermatitis, or allergies to any other medicines such as an
itchy skin rash or swelling of the lips, face and throat; have
uncontrolled, overactive thyroid gland; have a history of
heart problems such as heart attack, chest pain or stroke,
or untreated high blood pressure; or, are currently preg-
nant or breastfeeding. Initial screening will be conducted
by phone and will be repeated in person by a trained study
staff at the enrolment session. Screening will be overseen
by a qualified general practitioner.
Interventions
All participants will receive a standard paper-based self-
help quitting booklet, provided prior to an assigned quit
day. Participants randomized to either of the two pre-
quit groups will receive medication for two weeks of
active treatment (nicotine patches or varenicline) prior
to their assigned quit day, followed by up to 10 weeks of
post-quit treatment. Participants in the Standard Patch
Group will start active patch treatment on the morn-
ing of their assigned quit day; they will not receive
any medication during the pre-quit period. Medication
(patches or varenicline) will be distributed at study visits
(see below), with participants being provided enough
medication to last until the next scheduled visit.
As all participants must report smoking ≥10 cigarettes
per day to be eligible for enrolment, patch dose (for Pre-
Quit Patch and Standard Patch participants) will be deter-
mined by baseline body weight per Australian guidelines
[28]: participants who report a weight of ≥45 kg at enrol-
ment will start on 21 mg/24-hr patches while participants
who report a weight of <45 kg at enrolment will start on
14 mg/24-hr patches. Post-quit, participants will remain
on the same dose for 10 weeks; dose will not be titrated
downwards over the course of the study (again, in line
with Australian guidelines). Participants in the Varenicline
Group will receive 1 mg twice per day following a one-
week titration period (0.5 mg once per day for three days,
followed by 0.5 mg twice per day for four days). During
each study visit participants will be asked about medica-
tion use since the last study visit (including frequency of
use and adverse events) and any unused medication will
be collected.
Trial procedures
All participants will be asked to attend up to five study
visits and to monitor their smoking using a modified
smart-phone for a total of four weeks. Primary data col-
lection will take place via the customized smart-phone
(described below), with additional information obtained
via questionnaires at study visits. All measures have been
used and validated in the context of previous smoking
studies.
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At the beginning of the enrollment visit (Visit 1) eligible
and interested smokers will be given a detailed overview
of the study requirements and asked to provide written
informed consent. Participants will then be randomized to
their treatment group and assigned a quit date that will
fall 17 days after initial enrolment. Participants will be
instructed to quit smoking completely on their assigned
quit day. During the initial visit participants will also pro-
vide two expired air carbon monoxide (CO) samples (see
below), and a urine sample.
Baseline questionnaire assessment
During the initial visit, participants will be asked to
complete a detailed smoking history and demographic
characteristics questionnaire. Participants will be asked
about basic demographic characteristics (e.g., age, gender,
education, income, occupation, ethnicity, marital status
etc.), current smoking and smoking history (e.g., age at
initiation, cigarettes per day [CPD], years smoked, interest
in quitting, past quit efforts etc.), nicotine dependence (as
assessed by Fagerström Test for Nicotine Dependence
[29] and the Nicotine Dependence Syndrome Scale [30]),
alcohol use [31], feelings of depression [32], and satisfac-
tion gained from cigarettes (using the modified Cigarette
Evaluation Questionnaire [mCEQ]; [33]). As well as help-
ing to characterize our sample, responses to these items
will be used in our exploratory analyses of moderators of
treatment outcome.
Ecological Momentary Assessment (EMA) data collection
procedures
To collect near real-time data from participants as they
undertake their quit effort, participants will monitor their
smoking along with other study variables using modified
smart-phones. At Visit 1 all participants will be provided
with a smart-phone that has been stripped of its native
functionality. These devices will be loaded with custom
EMA data collection software designed by the study team.
Participants will be asked to carry this device with them at
all times for the following four weeks (until Visit 4).
Participants will be asked to indicate, by pressing a button
on the phone, each time they smoke a cigarette. The
device will log the time and date of these events and store
this data for later download and analysis.
During the pre-quit monitoring phase (i.e., Visit 1–3),
the phone will be used to administer three types of assess-
ments. Firstly, following 4–5 randomly selected cigarette
reports per day, participants will be asked to complete an
assessment of their current state (mood, withdrawal
severity, craving etc.) as well as contextual and situ-
ational details (where the participants is, who they are
with, what they are doing etc.). In addition to these “smok-
ing assessments” the device is programmed to “beep”
participants at a rate of approximately 4–5 times per day
for randomly-selected non-smoking assessments (“ran-
dom assessments”). During these assessments, partici-
pants will complete a series of items that parallels those
administered during smoking assessments. Finally, partici-
pants will also complete end-of-day assessments to gather
global reports on daily mood, craving and quitting self-
efficacy. The two weeks of post-quit EMA monitoring will
closely mirror that used in baseline monitoring, however
post-quit assessments will include additional items per-
taining to the lapse trigger(s) and the use (if any) of coping
mechanisms [21]. Items in the proposed EMA assess-
ments have been used and validated in previous EMA
studies, and are reported in detail in resulting publications
[21, 34]. Participants will be trained in EMA procedures
and on assessment content before field monitoring com-
mences formally (during Visit 1). Following procedures
established in previous successful EMA studies [21], the
second study visit (Visit 2) will be scheduled 2–4 days
after participants start EMA field monitoring, at which
time their data will be downloaded and checked, and they
will receive further EMA training (if necessary). At the
end of EMA monitoring (Visit 4) the study phones will be
retrieved and re-used with subsequent participants.
Study visits 2–5
Participants will complete a further 4 study visits as part
of the study. During each of these visits, CO and urine
samples will be obtained for all participants, and satis-
faction with smoking will be assessed using the mCEQ.
During Visit 2 (14 days prior to quit day), participants in
the Standard Patch group will be provided with one
patch, which they will be instructed to apply on the
morning of their assigned quit day. EMA data will be
downloaded from all participants and checked for com-
pliance, with extra training provided if necessary. Visit 3
will occur on a participants target quit day (17 days after
enrollment). During this visit, in addition to the general
tasks described above EMA data will be downloaded and
checked for protocol compliance with additional training
provided if necessary.
Study Visit 4 will occur 14 days after quit day and will
mark the end of the EMA monitoring period and all
phones will be handed back. The final study visit (Visit 5)
will occur 28 days after participants target quit day. Partic-
ipants who self-report 7-day point prevalent abstinence at
this visit, verified by expired air CO (see below), will be
provided a further six weeks of study medication. In
addition to the general study visit tasks, during their final
study visit participants will then complete an exit inter-
view during which they will be asked about the study
interventions and their experiences in the study. They will
also be fully debriefed and offered the opportunity to ask
any final questions about the study.
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Compensation and retention
In addition to receiving treatment, participants who
complete the entire study will be paid $50. Participants
will be paid for each visit that they complete, with the
per visit payment escalating over the course of study
visits ($10 at Visit 1, $20 at Visit 3, $20 at Visit 5).
Once enrolled, participants will be sent a reminder e-mail
and/or telephoned 24 h before a scheduled appointment.
At the end of each session, the next session will be
scheduled.
Verification of smoking status
At each study visit participants will be asked about
their current smoking status and any smoking that has oc-
curred since the previous study visit (via a calendar-
assisted 14-day timeline follow-back questionnaire). To
verify self-report, expired air CO samples will be obtained
at each study visit using a MICRO+ Smokerlyzer® (Bedfort
Scientific, UK). Two samples will be recorded at each visit
and if the average CO concentration of the two samples is
<8 ppm, this will be taken as evidence of abstinence.
Analytic plan
The proposed sample size (n = 216; 72 participants
per group) was determined by the requirements of the pri-
mary research questions—namely, detecting reductions in
satisfaction (H1) and craving (H2) scores, and smoking
rate (H3), between the Standard Patch and the two pre-
quit treatment groups at the end of the pre-quit treatment
period (Visit 3). In a previous study [19] we observed
moderate-to-large effects of pre-quit nicotine patch treat-
ment on self-reported satisfaction with smoking, craving,
and smoking rate during the pre-quit treatment period.
Using these reductions as a proxy for between-group
differences (assuming that these measures will not de-
crease during the pre-quit period for participants in the
Standard Patch group), a conservative estimate of within-
subject correlation of measures (0.5), our proposed sample
will afford >90 % power to detect a difference in these
measures. Our proposed sample size will also afford
>80 % power to detect an effect of smoking reduction dur-
ing the pre-quit phase on treatment outcomes (assessed at
Visit 5; H4). Based on an earlier study [19] we expect to
see ~6 % dropout before Visit 3 and as such we aim to
recruit and enroll 229 participants in order to achieve our
evaluable sample.
Our primary research questions involve reductions in
satisfaction with smoking (H1), cigarette craving (H2),
and smoking rate (H3) during the pre-quit treatment
phase. These questions will be tested separately for each
of the pre-quit groups using data gathered from the
EMA field monitoring using mixed models growth curve
analyses. The effect of smoking reduction on abstinence
(H4) will be assessed in two ways. Firstly, reduction
during the pre-quit phase will be used in a logistic re-
gression model to predict biochemically verified 7-day
point prevalent abstinence at Visit 5 (4 week abstinence).
Treatment group will be included as a covariate. This
outcome analysis will be conducted as intent-to-treat,
with all participants who are randomized (Visit 2) being
included in the analyses. Study dropouts will be counted
as treatment failures. Next, as traditional intent-to-treat
point prevalent abstinence analyses can obscure import-
ant aspects of the process of quitting smoking [13, 35],
we will also use the real-time EMA data to examine time
to first lapse using survival analyses.
In an exploratory analysis, we will compare the con-
text and consequences of smoking lapses across the
three treatment groups using data gathered during real-
time assessments of smoking lapses [34]. Finally, we
will examine whether individual differences in nicotine
metabolism moderate treatment outcome. Nicotine me-
tabolism will be expressed as the ratio of 3′-hydroxycoti-
nine to cotinine in urine, as well as directly measuring
their respective glucuronides (cotinine-N-glucuronide and
3′-hydroxycotinine-O-glucuronide). Instrumental analysis
of urines will be undertaken using an Ultra Performance
Liquid Chromatography-tandem mass spectrometry [36].
The main outcome measure will be total levels (free +
conjugated) of cotinine and 3′-hydroxycotinine.
Discussion
This study is designed to test the mechanism(s) though
which pre-quit treatments—specifically nicotine patches
and varenicline—aid cessation. Understanding how these
two pre-quit treatments influence abstinence may allow
for better tailoring of these efficacious treatments. Add-
itionally, understanding the effects of pre-quit treatment
with nicotine patch and varenicline may provide targets
for new pharmacotherapies.
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